Related references
Note: Only part of the references are listed.Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Patrick Vermersch et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Markus Axelsson et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
Valerie Jolivel et al.
BRAIN (2013)
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
Ralf Gold et al.
LANCET (2013)
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
H. Tedeholm et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
Jerry S. Wolinsky et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
Mohsen Khademi et al.
PLOS ONE (2013)
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Wolfgang Brueck et al.
ACTA NEUROPATHOLOGICA (2012)
Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity
Sara J. Ireland et al.
AUTOIMMUNITY (2012)
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
Kenneth P. Johnson
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
Afsaneh Shirani et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor
LANCET NEUROLOGY (2012)
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2012)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis
A. Scott Nielsen et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Progressive multiple sclerosis: pathology and pathogenesis
Hans Lassmann et al.
NATURE REVIEWS NEUROLOGY (2012)
Disease-modifying drugs for multiple sclerosis in pregnancy A systematic review
Ellen Lu et al.
NEUROLOGY (2012)
Fingolimod-associated macular edema Incidence, detection, and management
Nieraj Jain et al.
NEUROLOGY (2012)
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
A. J. Coles et al.
NEUROLOGY (2012)
Fingolimod for Multiple Sclerosis
Daniel Pelletier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis
Lars Bornsen et al.
PLOS ONE (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis
Anna Karin Hedstrom et al.
BRAIN (2011)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low
Janice Wong et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Carolina Holmen et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Stephen Sawcer et al.
NATURE (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
P. W. O'Connor et al.
NEUROLOGY (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
Gisa Ellrichmann et al.
PLOS ONE (2011)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2011)
Natalizumab Dosage Suspension: Are We Helping or Hurting?
Timothy W. West et al.
ANNALS OF NEUROLOGY (2010)
Anti-JC Virus Antibodies: Implications for PML Risk Stratification
Leonid Gorelik et al.
ANNALS OF NEUROLOGY (2010)
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Laura Piccio et al.
ARCHIVES OF NEUROLOGY (2010)
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray et al.
BRAIN (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen S. Tan et al.
LANCET NEUROLOGY (2010)
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis
Emma C. Tallantyre et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Environmental factors and their timing in adult-onset multiple sclerosis
Adam E. Handel et al.
NATURE REVIEWS NEUROLOGY (2010)
Breakthrough disease during interferon-β therapy in MS No signs of impaired biologic response
D. Hesse et al.
NEUROLOGY (2010)
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
M. Mehling et al.
NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
Richard A. Rudick et al.
LANCET NEUROLOGY (2009)
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis a phase I/II study. (vol 8, pg 244, 2009)
R. K. Burt et al.
LANCET NEUROLOGY (2009)
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos et al.
LANCET NEUROLOGY (2009)
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
P. Kivisakk et al.
NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
P. O'Connor et al.
LANCET NEUROLOGY (2009)
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Paul O'Connor et al.
LANCET NEUROLOGY (2009)
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study
Richard K. Burt et al.
LANCET NEUROLOGY (2009)
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
G. Comi et al.
LANCET (2008)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
Ludwig Kappos et al.
LANCET (2008)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
B cells and multiple sclerosis
Diego Franciotta et al.
LANCET NEUROLOGY (2008)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2008)
Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
Alasdair J. Coles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of Natalizumab Treatment on Foxp3+T Regulatory Cells
Max-Philipp Stenner et al.
PLOS ONE (2008)
Interferon-β treatment for multiple sclerosis
Robert A. Bermel et al.
NEUROTHERAPEUTICS (2007)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos et al.
NEUROLOGY (2006)
Oral fumaric acid esters for the treatment of active multiple sclerosis:: an open-label, baseline-controlled pilot study
S. Schimrigk et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
FTY720 treatment of kidney transplant patients: A differential effect on B cells, naive T cells, memory T cells and NK cells
Leonard M. B. Vaessen et al.
TRANSPLANT IMMUNOLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natural history of multiple sclerosis: a unifying concept
C Confavreux et al.
BRAIN (2006)
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis
C Tortorella et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis
D Miller et al.
LANCET NEUROLOGY (2005)
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
C Polman et al.
NEUROLOGY (2005)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Interrupted therapy -: Stopping and switching of the β-interferons prescribed for MS
HL Tremlett et al.
NEUROLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Linomide in relapsing and secondary progressive MS - Part I: Trial design and clinical results
JH Noseworthy et al.
NEUROLOGY (2000)
Share Paper
